Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

167%

5 of 3 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02589860Withdrawn

Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant

Role: lead

NCT02078102Phase 2Completed

A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

Role: lead

NCT02683525Phase 2Completed

Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Role: lead

NCT01303965Phase 1Terminated

Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

Role: lead

NCT01720264Phase 2Completed

Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

Role: lead

NCT00593554Phase 2Terminated

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Role: lead

All 6 trials loaded